a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare ...

Harmony Biosciences Holdings, Inc.’s HRMY share price has surged by 7.38%, which has investors questioning if this is right ...

CB1 = Endocannabinoid receptor 1; CCK = Cholecystokinin; DMN = Dorsomedial nucleus; GLP = Glucagon-like peptide; LHA = Lateral hypothalamic area; MCH = Melanin-concentrating hormone; NPY ...